These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18824842)

  • 1. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.
    Kotsianidis I; Bazdiara I; Anastasiades A; Spanoudakis E; Pantelidou D; Margaritis D; Bourikas G; De Coster R; De Porre P; Tsatalas C
    Acta Haematol; 2008; 120(1):51-6. PubMed ID: 18824842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
    Liesveld JL; Lancet JE; Rosell KE; Menon A; Lu C; McNair C; Abboud CN; Rosenblatt JD
    Leukemia; 2003 Sep; 17(9):1806-12. PubMed ID: 12970780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
    Korycka A; Smolewski P; Robak T
    Eur J Haematol; 2004 Dec; 73(6):418-26. PubMed ID: 15522064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro.
    Huang XK; Meyer P; Li B; Raza A; Preisler HD
    Leuk Lymphoma; 2003 Jan; 44(1):157-64. PubMed ID: 12691158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
    Navas TA; Mohindru M; Estes M; Ma JY; Sokol L; Pahanish P; Parmar S; Haghnazari E; Zhou L; Collins R; Kerr I; Nguyen AN; Xu Y; Platanias LC; List AA; Higgins LS; Verma A
    Blood; 2006 Dec; 108(13):4170-7. PubMed ID: 16940419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
    Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
    Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors: where are we now?
    Tsimberidou AM; Chandhasin C; Kurzrock R
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
    Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
    Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of tipifarnib in hematologic malignancies.
    Jabbour E; Kantarjian H; Cortes J
    Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.
    Cornelissen B; Lahorte C; Kersemans V; Capriotti G; Bonanno E; Signore A; Van de Wiele C; Dierckx RA; Slegers G
    Nucl Med Biol; 2005 Apr; 32(3):233-9. PubMed ID: 15820758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
    Epling-Burnette PK; Loughran TP
    Expert Opin Investig Drugs; 2010 May; 19(5):689-98. PubMed ID: 20402600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.
    Xue X; Lai KT; Huang JF; Gu Y; Karlsson L; Fourie A
    J Pharmacol Exp Ther; 2006 Apr; 317(1):53-60. PubMed ID: 16352705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipifarnib: farnesyl transferase inhibition at a crossroads.
    Mesa RA
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):313-9. PubMed ID: 16503848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
    Medeiros BC; Landau HJ; Morrow M; Lockerbie RO; Pitts T; Eckhardt SG
    Leukemia; 2007 Apr; 21(4):739-46. PubMed ID: 17268526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
    Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
    Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor.
    Mayani H; Baines P; Bowen DT; Jacobs A
    Leukemia; 1989 Jan; 3(1):29-32. PubMed ID: 2642575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
    Geryk-Hall M; Yang Y; Hughes DP
    Mol Cancer Ther; 2010 May; 9(5):1111-9. PubMed ID: 20406948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.